MorphoSys (MOR)

Business description

MorphoSys is a German biotechnology company that uses its proprietary antibody platforms to produce human antibodies for therapeutic use across a range of indications for partners and to develop its own pipeline.

Share price chart

Share chart

Stock data

Market cap.€1710.8m
Last close€64.65
High / Low (52 weeks)€86.8 / €57.2
Stock market listingDE
Forecast net cash (€m)297.1
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & Healthcare

Price performance

%1m3m12m
Actual(4.8)8.8(5.3)
Relative *(0.7)19.0(15)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Abzena Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Acucela
Addex Therapeutics Advanced Medical Solutions
Aegerion Pharmaceuticals Aeterna Zentaris
Agennix Alchemia
Alexza Pharmaceuticals Algeta
Alimera Sciences ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Animalcare Group Anteo Diagnostics
Anthera Pharmaceuticals Aratana Therapeutics
Ardea Biosciences Ardelyx
Arena Pharmaceuticals arGEN-X
Argos Therapeutics Ariad Pharmaceuticals
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Ascendis Pharma Astex Pharmaceuticals
Athersys Avacta Group
Avalanche Biotechnologies AVEO Pharmaceuticals
Avita Medical Balda
Basilea Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences Inv BioLineRx
Bionomics Bionor Pharma
Biota Holdings Biotie Therapies Corp
Biotron Bluebird Bio
BTG Can-Fite BioPharma
Capstone Therapeutics Carmat
Celldex Therapeutics Cellectis
Celyad Cerulean
Circadian Technologies Clavis Pharma
Cleveland BioLabs Clinigen Group
Clinuvel Consort Medical
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Delcath Systems Deltex Medical
Derma Sciences DiaSorin
Diaxonhit e-Therapeutics
EKF Diagnostics Emergent BioSolutions
Endocyte Epigenomics
Epistem Holdings Erytech Pharma
Esperion Therapeutics Evolva
Evotec Exact Sciences
Exelixis Formycon
Forward Pharma Futura Medical
Galapagos Galmed Pharmaceuticals
Genfit Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
GW Pharmaceuticals Halozyme Therapeutics
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunodiagnostic Systems Holdings ImmuPharma
Imprimis Pharmaceuticals Imugene
Incyte Corporation Infinity Pharmaceuticals
Innate Pharma Insmed
Invion Ion Beam Applications
Ipsogen Iridex
Ironwood Pharmaceuticals Islet Sciences
Ixico KaloBios Pharmaceuticals
Karolinska Development Keryx Biopharmaceuticals
LCA-Vision LeMaitre Vascular
Lifeline Scientific Ligand Pharmaceuticals
Lipocine Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene Midatech
Molecular Partners MolMed
Mologen AG Momenta Pharmaceuticals
Nanobiotix Nanosonics
Nektar Therapeutics NeoStem
Neovacs Newron Pharmaceuticals
NicOx NMC Health
NorDiag Nordion
NovaBay Pharmaceuticals Novogen
NPS Pharmaceuticals Ocata Therapeutics
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Ossur
OvaScience Oxford BioMedica
Pacific Edge Paion
Paladin Labs Patheon
Pharmacyclics Pharmaxis
Pharming Group Photocure
Phylogica Prescient Therapeutics
Prima BioMed Probiodrug
ProMetic Life Sciences Prosensa
Proteome Sciences QRxPharma
Quantum Pharmaceuticals Regeneus
Relmada Therapeutics ReNeuron Group
Resverlogix REVA Medical
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Simavita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
SymBio Pharmaceuticals Synairgen
Synergy Health Synta Pharmaceuticals
TearLab Corp Tekmira
TESARO Theraclion
Threshold Pharmaceuticals ThromboGenics
TiGenix Tissue Regenix
Tissue Therapies Tonix Pharmaceuticals
Topotarget Transgene
Trillium Therapeutics Trimel Pharmaceuticals
UCB UDG Healthcare
uniQure NV Universal Biosensors
Vectura Verastem
Verisante Technology Vernalis
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus VolitionRx
WaferGen Biosystems Wilex
Xencor Zafgen
Zealand Pharma Zeltia
Ziopharm Oncology

Company news

MorphoSys AG Reports Results for the First Three Months of 2015

Tue, 05 May 2015 05:03:45 GMT

MorphoSys AG: Announcement of the Convening of the AGM in Munich ...

Mon, 30 Mar 2015 11:48:45 GMT

MorphoSys AG : MorphoSys and Celgene Mutually Agree to End MOR202 ...

Thu, 26 Mar 2015 16:18:45 GMT

MorphoSys AG : MorphoSys to Receive Milestone Payment for Guselkumab ...

Mon, 13 Apr 2015 05:26:15 GMT

Annual General Meeting of MorphoSys AG Elects New Supervisory Board ...

Fri, 08 May 2015 13:52:30 GMT

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2013A 78.0 18.1 14.0 43.5 148.6 17.5
2014A 64.0 (1.8) (1.6) (1.3) N/A N/A
2015E 104.6 15.4 17.1 59.2 109.2 N/A
2016E 48.5 (41.3) (41.3) (105.7) N/A N/A

Last updated on 24/06/2015

Investment summary

MorphoSys has a broad portfolio of 23 antibodies in clinical studies, including four proprietary products with considerable potential after MOR209 entered Phase I. MOR103 is licensed to GSK for RA and other autoimmune indications, and we expect a Ph IIb trial to start soon. Data from a Phase I/II study in multiple myeloma with MOR202 will be presented at ASCO, and MorphoSys will look for a new partner to replace Celgene once the study is completed. Ph II studies with MOR208 in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia are ongoing. MorphoSys and partner Emergent BioSolution recently started a Ph I study with MOR209 in castration resistant prostate cancer. It has just acquired Lanthio Pharma, adding a pipeline of peptide therapies in preclinical development. In its partnered pipeline, J&J has now initiated five Ph III studies with guselkumab in psoriasis, but Roche terminated one of the Ph III trials with gantenerumab in Alzheimer's disease in Q414. It had a cash position of €350m on 31 March.

Last updated on 29/06/2015

Industry outlook

The pharmaceutical industry is out-licensing more drug discovery and developing more biological products, both trends that should benefit MorphoSys. Also, there is increasing demand for novel therapies, such as those in MorphoSys's proprietary pipeline.

Last updated on 29/06/2015

Key management

Gerald Moller, Chairman
Simon E. Moroney, CEO
Jens Holstein, CFO

Company address

Lena-Christ-Str. 48
82152 Martinsried/Planegg
Germany
+49 (0)89 / 899 27-0
View website